[Effect of etoposide for urogenital tumors].
Ten patients with urogenital tumors were treated with Etoposide. The dose schedule was 100 mg i.v. daily for 5 days and was repeated after 4-5 weeks. One patient with ureteral tumor experienced partial remission for 60 days and minor regression was achieved in 3 patients. The major side effects were leukopenia (60%) and thrombocytopenia (40%). Mean WBC nadir of 1050/mm3 occurred at 13.5 days and recovered quickly after a further 7.5 days.
D000230:Adenocarcinoma / Q000188:drug therapy; D000231:Adenocarcinoma, Papillary / Q000188:drug therapy; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011471:Prostatic Neoplasms / Q000188:drug therapy; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D014516:Ureteral Neoplasms / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy; D014565:Urogenital Neoplasms / Q000188:drug therapy*
D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D011034:Podophyllotoxin